1st Edition

Cytogenetics, FISH and Molecular Testing in Hematologic Malignancies

Edited By Wojciech Gorczyca Copyright 2008

    Cytogenetics, fluorescence in situ hybridization (FISH) and molecular tests, especially polymerase chain reaction (PCR), play an important role in the management of patients with hematologic malignancies by helping to establish the diagnosis, as well as predict prognosis, response to treatment and disease progression. Chromosomal and molecular abnormalities provide the most reliable criteria for classification of hematopoietic tumors and often comprise the basis for targeted therapy.

    Cytogenetics, FISH and Molecular Testing in Hematologic Malignancies, provides a review of chromosomal and molecular changes in hematologic malignancies and correlates the karyotypic and genetic abnormalities with morphology, immunophenotype and clinical data. With over 180 figures and diagnostic algorithms, this text is essential reading for all pathologists, hematopathologists, hematologic oncologists, cytogenetists, cytogenetic technologists and cell biologists.

    Chapter I. Introduction. Chapter II. Applications of cytogenetics, FISH and PCR in the diagnosis, prognosis and disease monitoring. Chapter III. Hematological malignancies: Correlation between morphology, phenotype and chromosomal/genetic markers.

    Biography

    Director of Hematopathology/Oncology Services (New York), Genzyme Genetics, USA

    "The intent of the author was to provide a helpful tool in diagnosing hematologic malignancies, as well as predicting prognosis, response to treatment, and disease progression. The author has reached his goals….This book will be useful primarily for practicing hematopathologists. Hematopathology fellows and pathology residents rotating in hematopathology, molecular genetics, and cytogenetics will also find it useful. In addition, it can be useful to practicing oncologists, hematology/oncology fellows, and residents in internal medicine….I would recommend it to anyone interested in hematologic malignancies." —Anamarija Morovic, MD (University of Cincinnati College of Medicine), Doody’s Reviews